autoroulettelapartage| Baili Tianheng (688506.SH): The first subject was enrolled in the Phase III clinical trial of BL-M07D1 for injection (HER2-ADC) in locally advanced or metastatic HER2-positive breast cancer

Gelonghui May 26 丨 Baili Tianheng (688506autoroulettelapartage.SH) announced that the company independently developedautoroulettelapartageInnovative biopharmaceutical injection BL-M07D1 (HER2-ADC) single agent for locally advanced or metastatic HER2-positive breast cancerautoroulettelapartageThe first subject has been enrolled in the Phase III clinical trial of.

BL-M07D1 is an ADC drug targeting HER2. Its indications are solid tumors such as breast cancer, gastric cancer, non-small cell lung cancer, gynecological tumors, and urinary system tumors. Recently, the clinical study of BL-M07D1 monotherapy in the treatment of HER2-positive breast cancer has entered the Phase III clinical trial stage and the first subject has been enrolled.